BioStock: Stayble Therapeutics looks towards its most important year so far
2023 has been an eventful year for Stayble Therapeutics with positive interim data from the study in degenerative disc disease, a rights issue, launch of disc herniation as new indication and successful partnering discussions at the Bio International Convention in Boston. The company has also recruited two new key players to the team, Dr. Jarkko Kalliomäki and Professor Daisuke Sakai. However, this is only the beginning of 2023, which could be the most important year so far for the company, according to CEO Andreas Gerward.
Read the full article at biostock.se:
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se